Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found that supplements containing saw palmetto may improve hair quality and density in patients with androgenetic alopecia and telogen effluvium, but more large-scale RCTs are needed for conclusive evidence.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

In this study, saw palmetto supplements showed varied effects on cell growth in vitro and did not significantly inhibit growth in the hamster flank organ model despite a notable trend.

This review discusses the presence of undeclared substances, including androgenic steroids, in sports supplements and emphasizes potential health risks, without providing new results; it advises caution and consultation on supplement use.

This review discusses current topical treatments, natural products, and complementary therapies for androgenetic alopecia, but it reports no new clinical results.

Testosterone therapy can improve sexual function in women but long-term safety is unclear.

Testosterone replacement can help menopausal women with various symptoms, but should be used carefully and is not yet officially licensed in the UK for women.

This review discusses the emerging pathophysiological factors and potential new therapies for androgenetic alopecia beyond traditional treatments, but reports no new results.

This study found that people taking Serenoa repens for more than 14 days had a higher likelihood of serious adverse reactions, particularly when also using multiple or interacting supplements, although higher SR doses were linked to lower risk.

This mini-review examines ethnopharmacological approaches to manage hair loss in postmenopausal women, highlighting promising botanical remedies like saw palmetto, rosemary oil, and ginseng. The authors underscore a need for more interdisciplinary trials and focus on traditional remedies' multifaceted benefits, while noting gaps in menopausal-specific evidence.

This study found that after 6 months of taking an oral supplement, patients with chronic telogen effluvium or androgenetic alopecia experienced a statistically significant increase in hair density and overall improved hair appearance compared to those taking a placebo, with the supplement being well tolerated.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

In this randomized controlled trial, the nutritional supplement PPT5 α was associated with increased terminal hair percentages and improved self-assessed hair parameters in women with early-stage androgenetic alopecia.

The document concludes that understanding health requires considering evolutionary perspectives on reproductive fitness, and recognizing the complexity of factors like diet, testosterone, and sexual orientation.

Finasteride caused serious side effects and led to six suicides.

This review discusses how the HSD3B1(1245C) genotype may impact androgen physiology and the progression of castration-resistant prostate cancer, and does not report new experimental results.

This article reviews the limited evidence on testosterone therapy for premenopausal women and notes a lack of long-term safety and effectiveness data for this population.

This article discusses the sexual health issues faced by postmenopausal women and highlights the need for more research and tailored treatments, but it reports no new clinical results.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

This review discusses the clinical implications of female androgen deficiency and evaluates treatment options, emphasizing the need for cautious use of replacement therapy in women with severe deficiency and matching symptoms.

Various treatments exist for hair loss, but more research is needed for better options.

This article evaluated evidence on finasteride's effects on male reproductive health, finding contradictory data about its adverse effects, but consensus that such cases are infrequent in research and clinical settings.

This article reviews various treatments for alopecia, highlighting that minoxidil, finasteride, PRP therapy, and hair transplants are the most commonly used options, but it reports no new clinical results.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

This review discusses the limited objective evidence for using finasteride in women with alopecia, suggesting that it could be considered for those who don't benefit from minoxidil, but reports no new clinical results.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

This review identifies evidence of sexual adverse effects, particularly linked to finasteride, in men using systemic dermatologic medications but reports no new clinical findings.